TGFB1 and neoplasm: The study systematically identified key research hotspots within this field, encompassing immune checkpoint inhibitors, single-cell RNA sequencing technology, the TME heterogeneity, the TGFβ signaling pathway, and the impact of PARP inhibitors on the tumor immune microenvironment (TIME).